Skip to content

SPIN PHARMA — home

Evidence, labelled
Breakthroughs
Significant discoveries, therapy advances and trial results — with every early-stage finding clearly labelled for what it is.
Open Breakthroughs
Latest storyA Drug That Works in Cells Isn’t a Cure: How to Read a Biotech Breakthrough
Algorithms meet the clinic
AI + Medicine
Drug discovery, diagnostics, AI-assisted MRI and imaging, clinical trials, robotics, wearables and hospital workflows.
Open AI + Medicine
Latest storyCan AI Spot Cancer Earlier? Where Imaging Helps and Where False Alarms Matter
Science ≠ share price
Companies + Stocks
Public companies and startups, pipelines, partnerships, funding and milestones — scientific progress kept separate from market performance.
Open Companies + Stocks
Latest storyThe Biotech Startup Map: How Young Companies Move From Discovery to Patients
Hardware for health
DeepTech + MedTech
Imaging, surgical technology, sensors, lab automation, organoids, bioprinting, brain health and next-generation devices.
Open DeepTech + MedTech
Latest storyThe MRI Reinvention: Faster Scans, Better Images, and the Real Role of AI
Read, write, edit
Genome + Cells
Sequencing, gene editing, gene therapy, epigenetics, cell therapies — and what genomic data can and cannot tell us.
Open Genome + Cells
Latest storyDecode the Genome: What Sequencing Can Tell Us—and What It Cannot
Many diseases, many answers
Cancer Frontiers
Treatments by mechanism, early detection, precision oncology, immunotherapy and prevention research. Cancer is many diseases — we report it that way.
Open Cancer Frontiers
Latest storyIs There a Cure for Cancer? The Better Question Is: Which Cancer, at What Stage, and With Which Treatment?
Healthspan, honestly
Longevity
Aging biology, healthspan, clinical evidence and interventions under study — with an honest line between hype and evidence.
Open Longevity
Latest storyThe Cell Health Frontier: Senescence, Mitochondria, and the Search for Better Healthspan
Explore
The Lab
Thoughtful “What if?” experiments. Speculation is always labelled — and polls are never evidence.
Open The Lab
FeaturedWhat if an MRI scan took a fraction of the time?
Explore
Play + Learn
Educational games, quizzes, visual explainers and videos.
Open Play + Learn
FeaturedDrug Development Journey
Explore
Resources
Universities, research institutions, journals, public databases, trials and a glossary — plus who we are.
Open Resources

Get The Spin Brief About Spin Pharma

Get The Spin Brief

Search

CRISPR MRI immunotherapy clinical trial organoids biological age

Home
Phase 3

Development / evidence stage

Phase 3

Cancer Frontiers

Intismeran autogene (V940 / mRNA-4157)

Phase 3 INTerpath-001 (NCT05933577) met its primary recurrence-free survival endpoint, announced Aug. 19, 2026; the companies say they will engage regulators on filings (company release).

Pipeline entry

SPIN PHARMA — home

See what’s next in health. Evidence-first reporting on biotech, AI, genomics, medtech, cancer research and longevity.

The Spin Brief — weekly, concise, evidence-first.

Email address

I agree to receive The Spin Brief by email and accept the privacy policy. Unsubscribe any time with one click.

Leave this empty

Sections

Breakthroughs
AI + Medicine
Companies + Stocks
DeepTech + MedTech
Genome + Cells
Cancer Frontiers
Longevity

Learn & explore

The Lab
Play + Learn
Videos
Pipeline tracker
Company directory
Resources
Glossary
Explore & filter

Spin Pharma

About Spin Pharma
Editorial standards
Disclosures & sponsorship
The Spin Brief newsletter
Contact
Privacy & consent
Our network

Not medical or investment advice. Spin Pharma publishes general education and journalism. It does not diagnose, recommend treatments or recommend securities. Talk to a qualified clinician about your health, and a licensed adviser about investments. Company profiles and watchlists are informational.

© 2026 Spin Pharma · A Mass Density, Inc. publication · Illustrations are original artwork and do not depict real patients, scans or trial results.